The objective response rate (ORR) for anti-CTLA-4 ipilimumab (Yervoy) in melanoma was 10.9%, with a high-grade treatment-related adverse event rate of 15% [9]; for anti-PD-1 Pembrolizumab (Keytruda) in advanced melanoma—33% ORR, with 14% high-grade treatment-related adverse events [19]; for anti-PD-L1 Avelumab (Bavencio) in urothelial carcinoma—17% ORR, with 8% high-grade treatment adverse events [20]. Here, PDCD1 is linked to urothelial carcinoma.